Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain

Virology

Volumn 405, Issue 1, 2010, Pages 81-92

  Braibant, Martine ^a   Xie, Jing ^b,c   Samri, Assia ^b,c   Agut, Henri ^d   Autran, Brigitte ^b,c,d   Barin, Francis ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b Laboratoire d'Immunologie Cellulaire et Tissulaire CNRS URA 625   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

HIV 1; HLA B57; Long term nonprogressor; Nef; Superinfection

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; HLA B57 ANTIGEN; NEF PROTEIN; VIF PROTEIN; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL LOSS; CELLULAR IMMUNITY; CLADISTICS; DEFECTIVE VIRUS; DISEASE COURSE; DNA ISOLATION; GENE EXPRESSION; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; PRIORITY JOURNAL; PROVIRUS; SUPERINFECTION; UNINDEXED SEQUENCE; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77955514287     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.05.026     Document Type: Article

References (77)

1. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 2007, 204(10):2473-2485.
2. Almond N., Kent K., Cranage M., Rud E., Clarke B., Stott E.J. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995, 345(8961):1342-1344.
3. + T-cell responses containing replication of the primary virus. Nature 2002, 420(6914):434-439.
4. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 2000, 6(2):200-206.
5. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455(7213):613-619.
6. Birch M.R., Learmont J.C., Dyer W.B., Deacon N.J., Zaunders J.J., Saksena N., Cunningham A.L., Mills J., Sullivan J.S. An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J. Clin. Virol. 2001, 22(3):263-270.
7. Blish C.A., Dogan O.C., Derby N.R., Nguyen M.A., Chohan B., Richardson B.A., Overbaugh J. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J. Virol. 2008, 82(24):12094-12103.
8. Braibant M., Brunet S., Costagliola D., Rouzioux C., Agut H., Katinger H., Autran B., Barin F. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 2006, 20(15):1923-1930.
9. Braibant M., Agut H., Rouzioux C., Costagliola D., Autran B., Barin F. Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies. J. Acquir. Immune Defic. Syndr. 2008, 47(3):274-284.
10. Brockman M.A., Schneidewind A., Lahaie M., Schmidt A., Miura T., Desouza I., Ryvkin F., Derdeyn C.A., Allen S., Hunter E., Mulenga J., Goepfert P.A., Walker B.D., Allen T.M. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 2007, 81(22):12608-12618.
11. Calugi G., Montella F., Favalli C., Benedetto A. Entire genome of a strain of human immunodeficiency virus type 1 with a deletion of nef that was recovered 20years after primary infection: large pool of proviruses with deletions of env. J. Virol. 2006, 80(23):11892-11896.
12. Candotti D., Costagliola D., Joberty C., Bonduelle O., Rouzioux C., Autran B., Agut H. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J. Med. Virol. 1999, 58(3):256-263.
13. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J. Med. 1995, 332(4):201-208.
14. + T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 1998, 12(13):1591-1600.
15. Casado C., Pernas M., Alvaro T., Sandonis V., Garcia S., Rodriguez C., del Romero J., Grau E., Ruiz L., Lopez-Galindez C. Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 disease. J. Infect. Dis. 2007, 196(6):895-899.
16. Cecilia D., Kleeberger C., Munoz A., Giorgi J.V., Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J. Infect. Dis. 1999, 179(6):1365-1374.
17. Churchill M., Sterjovski J., Gray L., Cowley D., Chatfield C., Learmont J., Sullivan J.S., Crowe S.M., Mills J., Brew B.J., Wesselingh S.L., McPhee D.A., Gorry P.R. Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J. Infect. Dis. 2004, 190(12):2181-2186.
18. Churchill M.J., Rhodes D.I., Learmont J.C., Sullivan J.S., Wesselingh S.L., Cooke I.R., Deacon N.J., Gorry P.R. Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J. Virol. 2006, 80(2):1047-1052.
19. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206(2):935-944.
20. Cranage M.P., Whatmore A.M., Sharpe S.A., Cook N., Polyanskaya N., Leech S., Smith J.D., Rud E.W., Dennis M.J., Hall G.A. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997, 229(1):143-154.
21. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258(5090):1938-1941.
22. Dyer W.B., Ogg G.S., Demoitie M.A., Jin X., Geczy A.F., Rowland-Jones S.L., McMichael A.J., Nixon D.F., Sullivan J.S. Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J. Virol. 1999, 73(1):436-443.
23. Enose Y., Ui M., Miyake A., Suzuki H., Uesaka H., Kuwata T., Kunisawa J., Kiyono H., Takahashi H., Miura T., Hayami M. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 2002, 298(2):306-316.
24. Ferrantelli F., Rasmussen R.A., Buckley K.A., Li P.L., Wang T., Montefiori D.C., Katinger H., Stiegler G., Anderson D.C., McClure H.M., Ruprecht R.M. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 2004, 189(12):2167-2173.
25. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191(5):654-665.
26. Foster J.L., Garcia J.V. HIV-1 Nef: at the crossroads. Retrovirology 2008, 5:84.
27. Galetto R., Moumen A., Giacomoni V., Veron M., Charneau P., Negroni M. The structure of HIV-1 genomic RNA in the gp120 gene determines a recombination hot spot in vivo. J. Biol. Chem. 2004, 279(35):36625-36632.
28. Galetto R., Giacomoni V., Veron M., Negroni M. Dissection of a circumscribed recombination hot spot in HIV-1 after a single infectious cycle. J. Biol. Chem. 2006, 281(5):2711-2720.
29. Geyer M., Fackler O.T., Peterlin B.M. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2001, 2(7):580-585.
30. Gilbert P.B., Ackers M.L., Berman P.W., Francis D.P., Popovic V., Hu D.J., Heyward W.L., Sinangil F., Shepherd B.E., Gurwith M. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J. Infect. Dis. 2005, 192(6):974-983.
31. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., Heyward W.L., Jobes D.V., Popovic V., Self S.G., Sinangil F., Burke D., Berman P.W. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 2005, 191(5):666-677.
32. Gorry P.R., Churchill M., Learmont J., Cherry C., Dyer W.B., Wesselingh S.L., Sullivan J.S. Replication-dependent pathogenicity of attenuated nef-deleted HIV-1 in vivo. J. Acquir. Immune Defic. Syndr. 2007, 46(4):390-394.
33. Greenough T.C., Somasundaran M., Brettler D.B., Hesselton R.M., Alimenti A., Kirchhoff F., Panicali D., Sullivan J.L. Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 1994, 10(4):395-403.
34. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 1999, 41:95-98.
35. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W., Marx P.A., Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15(8):951-954.
36. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5(5):e1000433.
37. Hofmann-Lehmann R., Vlasak J., Williams A.L., Chenine A.L., McClure H.M., Anderson D.C., O'Neil S., Ruprecht R.M. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 2003, 17(2):157-166.
38. Jost S., Bernard M.C., Kaiser L., Yerly S., Hirschel B., Samri A., Autran B., Goh L.E., Perrin L. A patient with HIV-1 superinfection. N Engl J. Med. 2002, 347(10):731-736.
39. Kaslow R.A., Carrington M., Apple R., Park L., Munoz A., Saah A.J., Goedert J.J., Winkler C., O'Brien S.J., Rinaldo C., Detels R., Blattner W., Phair J., Erlich H., Mann D.L. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 1996, 2(4):405-411.
40. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., Rathnavalu P., Moore C., Pfafferott K.J., Hilton L., Zimbwa P., Moore S., Allen T., Brander C., Addo M.M., Altfeld M., James I., Mallal S., Bunce M., Barber L.D., Szinger J., Day C., Klenerman P., Mullins J., Korber B., Coovadia H.M., Walker B.D., Goulder P.J. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004, 432(7018):769-775.
41. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 1980, 16(2):111-120.
42. Kirchhoff F., Greenough T.C., Brettler D.B., Sullivan J.L., Desrosiers R.C. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J. Med. 1995, 332(4):228-232.
43. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 2001, 58:19-42.
44. Kumar A., Mukherjee S., Shen J., Buch S., Li Z., Adany I., Liu Z., Zhuge W., Piatak M., Lifson J., McClure H., Narayan O. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Virology 2002, 301(2):189-205.
45. Kumar S., Tamura K., Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 2004, 5(2):150-163.
46. Lambotte O., Boufassa F., Madec Y., Nguyen A., Goujard C., Meyer L., Rouzioux C., Venet A., Delfraissy J.F. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 2005, 41(7):1053-1056.
47. Le Gall S., Erdtmann L., Benichou S., Berlioz-Torrent C., Liu L., Benarous R., Heard J.M., Schwartz O. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998, 8(4):483-495.
48. Learmont J.C., Geczy A.F., Mills J., Ashton L.J., Raynes-Greenow C.H., Garsia R.J., Dyer W.B., McIntyre L., Oelrichs R.B., Rhodes D.I., Deacon N.J., Sullivan J.S. Immunologic and virologic status after 14 to 18years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J. Med. 1999, 340(22):1715-1722.
49. Magierowska M., Theodorou I., Debre P., Sanson F., Autran B., Riviere Y., Charron D., Costagliola D. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 1999, 93(3):936-941.
50. Malim M.H., Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3(6):388-398.
51. 1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J. Infect. Dis. 2005, 191(12):2053-2063.
52. Martinez-Picado J., Prado J.G., Fry E.E., Pfafferott K., Leslie A., Chetty S., Thobakgale C., Honeyborne I., Crawford H., Matthews P., Pillay T., Rousseau C., Mullins J.I., Brander C., Walker B.D., Stuart D.I., Kiepiela P., Goulder P. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 2006, 80(7):3617-3623.
53. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., Birx D.L. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73(5):4009-4018.
54. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6(2):207-210.
55. + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 2004, 200(6):761-770.
56. Montefiori D.C., Baba T.W., Li A., Bilska M., Ruprecht R.M. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. J. Immunol. 1996, 157(12):5528-5535.
57. + T lymphocyte responsiveness to the HW9 epitope in Nef. J. Infect. Dis. 2008, 197(6):871-879.
58. Ngo-Giang-Huong N., Candotti D., Goubar A., Autran B., Maynart M., Sicard D., Clauvel J.P., Agut H., Costagliola D., Rouzioux C. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res. Hum. Retroviruses 2001, 17(15):1435-1446.
59. Pace C., Keller J., Nolan D., James I., Gaudieri S., Moore C., Mallal S. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 2006, 80(18):9259-9269.
60. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., Bolognesi D.P., Fauci A.S., Montefiori D.C. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J. Infect. Dis. 1997, 176(4):924-932.
61. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72(4):2855-2864.
62. + T cell counts. J. Infect. Dis. 2005, 192(1):46-55.
63. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4(4):406-425.
64. Sawai E.T., Hamza M.S., Ye M., Shaw K.E., Luciw P.A. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J. Virol. 2000, 74(4):2038-2045.
65. Shibata R., Siemon C., Czajak S.C., Desrosiers R.C., Martin M.A. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J. Virol. 1997, 71(11):8141-8148.
66. Steinbrook R. One step forward, two steps back-will there ever be an AIDS vaccine?. N Engl J. Med. 2007, 357(26):2653-2655.
67. Stipp H.L., Kumar A., Narayan O. Characterization of immune escape viruses from a macaque immunized with live-virus vaccine and challenged with pathogenic SHIVKU-1. AIDS Res. Hum. Retroviruses 2000, 16(15):1573-1580.
68. + T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J. Virol. 2007, 81(14):7725-7731.
69. Streeck H., Li B., Poon A.F., Schneidewind A., Gladden A.D., Power K.A., Daskalakis D., Bazner S., Zuniga R., Brander C., Rosenberg E.S., Frost S.D., Altfeld M., Allen T.M. Immune-driven recombination and loss of control after HIV superinfection. J. Exp. Med. 2008, 205(8):1789-1796.
70. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22(22):4673-4680.
71. Verity E.E., Zotos D., Wilson K., Chatfield C., Lawson V.A., Dwyer D.E., Cunningham A., Learmont J., Dyer W., Sullivan J., Churchill M., Wesselingh S.L., Gabuzda D., Gorry P.R., McPhee D.A. Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions. J. Virol. 2007, 81(17):9268-9278.
72. Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320(5877):760-764.
73. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46(6):1896-1905.
74. Wyand M.S., Manson K.H., Garcia-Moll M., Montefiori D., Desrosiers R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 1996, 70(6):3724-3733.
75. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J. Virol. 1999, 73(10):8356-8363.
76. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280(5371):1884-1888.
77. Yang O.O., Nguyen P.T., Kalams S.A., Dorfman T., Gottlinger H.G., Stewart S., Chen I.S., Threlkeld S., Walker B.D. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J. Virol. 2002, 76(4):1626-1631.